Search

Your search keyword '"Dremaine A"' showing total 11 results
Start Over Author "Dremaine A"
11 results on '"Dremaine A"'

1. Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes

Author

McKay, S., Haymond, M., Anderson, B., Bush, C., Gunn, S., Holden, H., Jones, S.M., Jeha, G., McGirk, S., Thamotharan, S., Cuttler, L., Abrams, E., Casey, T., Dahms, W., Ievers-Landis, C., Kaminski, B., Koontz, M., MacLeish, S., McGuigan, P., Narasimhan, S., Geffner, M., Barraza, V., Chang, N., Conrad, B., Dreimane, D., Estrada, S., Fisher, L., Fleury-Milfort, E., Hernandez, S., Hollen, B., Kaufman, F., Law, E., Mansilla, V., Miller, D., Muñoz, C., Ortiz, R., Ward, A., Wexler, K., Xu, Y.K., Yasuda, P., Berkowitz, R., Boyd, S., Johnson, B., Kaplan, J., Keating, C., Lassiter, C., Lipman, T., McGinley, G., McKnight, H., Schwartzman, B., Willi, S., Arslanian, S., Foster, S., Galvin, B., Hannon, T., Kriska, A., Marcus, M., Songer, T., Venditti, E., Goland, R., Gallagher, D., Kringas, P., Leibel, N., Ng, D., Ovalles, M., Seidman, D., Laffel, L., Goebel-Fabbri, A., Hall, M., Higgins, L., Keady, J., Malloy, M., Milaszewski, K., Rasbach, L., Nathan, D.M., Angelescu, A., Bissett, L., Ciccarelli, C., Delahanty, L., Goldman, V., Hardy, O., Larkin, M., Levitsky, L., McEachern, R., Norman, D., Nwosu, D., Park-Bennett, S., Richards, D., Sherry, N., Steiner, B., Tollefsen, S., Carnes, S., Dempsher, D., Flomo, D., Whelan, T., Wolff, B., Bowerman, D., Bristol, S., Bulger, J., Hartsig, J., Izquierdo, R., Kearns, J., Saletsky, R., Trief, P., Zeitler, P., Abramson, N., Bradhurst, A., Celona-Jacobs, N., Higgins, J., Kelsey, M., Klingensmith, G., Witten, T., Copeland, K., Boss, E., Brown, R., Chadwick, J., Chalmers, L., Chernausek, S., Hebensperger, A., Macha, C., Newgent, R., Nordyke, A., Olson, D., Poulsen, T., Pratt, L., Preske, J., Schanuel, J., Sternlof, S., Lynch, J., Amodei, N., Barajas, R., Cody, C., Hale, D., Hernandez, J., Ibarra, C., Morales, E., Rivera, S., Rupert, G., Wauters, A., White, N., Arbeláez, A., Jones, J., Jones, T., Sadler, M., Tanner, M., Timpson, A., Welch, R., Caprio, S., Grey, M., Guandalini, C., Lavietes, S., Rose, P., Syme, A., Tamborlane, W., Hirst, K., Edelstein, S., Feit, P., Grover, N., Long, C., Pyle, L., Linder, B., Harting, J., Shepherd, J., Fan, B., Marquez, L., Sherman, M., Wang, J., Nichols, M., Mayer-Davis, E., Liu, Y., Lima, J., Puccella, J., Ricketts, E., Danis, R., Domalpally, A., Goulding, A., Neill, S., Vargo, P., Wilfley, D., Aldrich-Rasche, D., Franklin, K., Massmann, C., O'Brien, D., Patterson, J., Tibbs, T., Van Buren, D., Palmert, M., Ratner, R., Dremaine, D., Silverstein, J., Levitt Katz, Lorraine E., Bacha, Fida, Gidding, Samuel S., Weinstock, Ruth S., El ghormli, Laure, Libman, Ingrid, Nadeau, Kristen J., Porter, Kristin, and Marcovina, Santica

Published
2018
Full Text
View/download PDF

2. Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study

Author

McKay, S., Haymond, M., Anderson, B., Bush, C., Gunn, S., Holden, H., Jones, S.M., Jeha, G., McGirk, S., Thamotharan, S., Cuttler, L., Abrams, E., Casey, T., Dahms, W., Ievers-Landis, C., Kaminski, B., Koontz, M., MacLeish, S., McGuigan, P., Narasimhan, S., Geffner, M., Barraza, V., Chang, N., Conrad, B., Dreimane, D., Estrada, S., Fisher, L., Fleury-Milfort, E., Hernandez, S., Hollen, B., Kaufman, F., Law, E., Mansilla, V., Miller, D., Muñoz, C., Ortiz, R., Ward, A., Wexler, K., Xu, Y.K., Yasuda, P., Levitt Katz, L., Berkowitz, R., Boyd, S., Johnson, B., Kaplan, J., Keating, C., Lassiter, C., Lipman, T., McGinley, G., McKnight, H., Schwartzman, B., Willi, S., Arslanian, S., Bacha, F., Foster, S., Galvin, B., Hannon, T., Kriska, A., Libman, I., Marcus, M., Porter, K., Songer, T., Venditti, E., Goland, R., Gallagher, D., Kringas, P., Leibel, N., Ng, D., Ovalles, M., Seidman, D., Laffel, L., Goebel-Fabbri, A., Hall, M., Higgins, L., Keady, J., Malloy, M., Milaszewski, K., Rasbach, L., Nathan, D.M., Angelescu, A., Bissett, L., Ciccarelli, C., Delahanty, L., Goldman, V., Hardy, O., Larkin, M., Levitsky, L., McEachern, R., Norman, D., Nwosu, D., Park-Bennett, S., Richards, D., Sherry, N., Steiner, B., Tollefsen, S., Carnes, S., Dempsher, D., Flomo, D., Whelan, T., Wolff, B., Weinstock, R., Bowerman, D., Bristol, S., Bulger, J., Hartsig, J., Izquierdo, R., Kearns, J., Saletsky, R., Trief, P., Zeitler, P., Abramson, N., Bradhurst, A., Celona-Jacobs, N., Higgins, J., Kelsey, M., Klingensmith, G., Nadeau, K., Witten, T., Copeland, K., Boss, E., Brown, R., Chadwick, J., Chalmers, L., Chernausek, S., Hebensperger, A., Macha, C., Newgent, R., Nordyke, A., Olson, D., Poulsen, T., Pratt, L., Preske, J., Schanuel, J., Sternlof, S., Lynch, J., Amodei, N., Barajas, R., Cody, C., Hale, D., Hernandez, J., Ibarra, C., Morales, E., Rivera, S., Rupert, G., Wauters, A., White, N., Arbeláez, A., Jones, J., Jones, T., Sadler, M., Tanner, M., Timpson, A., Welch, R., Caprio, S., Grey, M., Guandalini, C., Lavietes, S., Rose, P., Syme, A., Tamborlane, W., Hirst, K., Edelstein, S., Feit, P., Grover, N., Long, C., Pyle, L., Linder, B., Marcovina, S.M., Harting, J., Shepherd, J., Fan, B., Marquez, L., Sherman, M., Wang, J., Nichols, M., Mayer-Davis, E., Liu, Y., Lima, J., Gidding, S., Puccella, J., Ricketts, E., Danis, R., Domalpally, A., Goulding, A., Neill, S., Vargo, P., Wilfley, D., Aldrich-Rasche, D., Franklin, K., Massmann, C., O'Brien, D., Patterson, J., Tibbs, T., Van Buren, D., Palmert, M., Ratner, R., Dremaine, D., Silverstein, J., Gidding, Samuel S., Bacha, Fida, Bjornstad, Petter, Levitt Katz, Lorraine E., Levitsky, Lynne L., Lynch, Jane, Tryggestad, Jeanie B., Weinstock, Ruth S., El ghormli, Laure, and Lima, Joao A.C.

Published
2018
Full Text
View/download PDF

3. Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study

Author

Gidding, Samuel S., Bacha, Fida, Bjornstad, Petter, Katz, Lorraine E. Levitt, Levitsky, Lynne L., Lynch, Jane, Tryggestad, Jeanie B., Weinstock, Ruth S., El ghormli, Laure, Lima, Joao A.C., McKay, S., Haymond, M., Anderson, B., Bush, C., Gunn, S., Holden, H., Jones, S. M., Jeha, G., McGirk, S., Thamotharan, S., Cuttler, L., Abrams, E., Casey, T., Dahms, W., Ievers-Landis, C., Kaminski, B., Koontz, M., MacLeish, S., McGuigan, P., Narasimhan, S., Geffner, M., Barraza, V., Chang, N., Conrad, B., Dreimane, D., Estrada, S., Fisher, L., Fleury-Milfort, E., Hernandez, S., Hollen, B., Kaufman, F., Law, E., Mansilla, V., Miller, D., Muñoz, C., Ortiz, R., Ward, A., Wexler, K., Xu, Y. K., Yasuda, P., Katz, Levitt L., Berkowitz, R., Boyd, S., Johnson, B., Kaplan, J., Keating, C., Lassiter, C., Lipman, T., McGinley, G., McKnight, H., Schwartzman, B., Willi, S., Arslanian, S., Bacha, F., Foster, S., Galvin, B., Hannon, T., Kriska, A., Libman, I., Marcus, M., Porter, K., Songer, T., Venditti, E., Goland, R., Gallagher, D., Kringas, P., Leibel, N., Ng, D., Ovalles, M., Seidman, D., Laffel, L., Goebel-Fabbri, A., Hall, M., Higgins, L., Keady, J., Malloy, M., Milaszewski, K., Rasbach, L., Nathan, D. M., Angelescu, A., Bissett, L., Ciccarelli, C., Delahanty, L., Goldman, V., Hardy, O., Larkin, M., Levitsky, L., McEachern, R., Norman, D., Nwosu, D., Park-Bennett, S., Richards, D., Sherry, N., Steiner, B., Tollefsen, S., Carnes, S., Dempsher, D., Flomo, D., Whelan, T., Wolff, B., Weinstock, R., Bowerman, D., Bristol, S., Bulger, J., Hartsig, J., Izquierdo, R., Kearns, J., Saletsky, R., Trief, P., Zeitler, P., Abramson, N., Bradhurst, A., Celona-Jacobs, N., Higgins, J., Kelsey, M., Klingensmith, G., Nadeau, K., Witten, T., Copeland, K., Boss, E., Brown, R., Chadwick, J., Chalmers, L., Chernausek, S., Hebensperger, A., Macha, C., Newgent, R., Nordyke, A., Olson, D., Poulsen, T., Pratt, L., Preske, J., Schanuel, J., Sternlof, S., Lynch, J., Amodei, N., Barajas, R., Cody, C., Hale, D., Hernandez, J., Ibarra, C., Morales, E., Rivera, S., Rupert, G., Wauters, A., White, N., Arbeláez, A., Jones, J., Jones, T., Sadler, M., Tanner, M., Timpson, A., Welch, R., Caprio, S., Grey, M., Guandalini, C., Lavietes, S., Rose, P., Syme, A., Tamborlane, W., Hirst, K., Edelstein, S., Feit, P., Grover, N., Long, C., Pyle, L., Linder, B., Marcovina, S. M., Harting, J., Shepherd, J., Fan, B., Marquez, L., Sherman, M., Wang, J., Nichols, M., Mayer-Davis, E., Liu, Y., Lima, J., Gidding, S., Puccella, J., Ricketts, E., Danis, R., Domalpally, A., Goulding, A., Neill, S., Vargo, P., Wilfley, D., Aldrich-Rasche, D., Franklin, K., Massmann, C., O’Brien, D., Patterson, J., Tibbs, T., Van Buren, D., Palmert, M., Ratner, R., Dremaine, D., and Silverstein, J.

Published
2018
Full Text
View/download PDF

4. Successful tyrosine kinase inhibitor discontinuation outside clinical trials : data from the population-based Swedish chronic myeloid leukaemia registry

Author

Leif Stenke, Berit Markevärn, Lovisa Wennström, Arta Dremaine, Fredrik Sandin, Anna Lübking, Torsten Dahlén, Ulla Olsson-Strömberg, Stina Söderlund, Hans Wadenvik, Johan Richter, Anders Själander, Hjalmar Flygt, Karin Olsson, Kristina Myhr-Eriksson, and Martin Höglund

Subjects
Adult, Male, medicine.medical_specialty, medicine.drug_class, chronic myeloid leukaemia, Population, ABL, Chronic myeloid leukaemia, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, tyrosine kinase inhibitor, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, medicine, Humans, Registries, Hematologi, Adverse effect, education, Protein Kinase Inhibitors, BCR-ABL, Aged, Retrospective Studies, Sweden, Pregnancy, education.field_of_study, BCR&#8208, business.industry, BCR‐ ABL, discontinuation, Retrospective cohort study, Hematology, Middle Aged, medicine.disease, Discontinuation, respiratory tract diseases, Clinical trial, 030220 oncology & carcinogenesis, Female, business, 030215 immunology, Follow-Up Studies
Abstract

Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outside clinical trials are limited. In this retrospective study utilising the Swedish CML registry, we examined TKI discontinuation in a population-based setting. Out of 584 patients diagnosed with chronic-phase CML (CML-CP) in 2007-2012, 548 had evaluable information on TKI discontinuation. With a median follow-up of nine years from diagnosis, 128 (23%) discontinued TKI therapy (>= 1 month) due to achieving a DMR (deep molecular response) and 107 (20%) due to other causes (adverse events, allogeneic stem cell transplant, pregnancy, etc). Among those stopping in DMR, 49% re-initiated TKI treatment (median time to restart 4 center dot 8 months). In all, 38 patients stopped TKI within a clinical study and 90 outside a study. After 24 months 41 center dot 1% of patients discontinuing outside a study had re-initiated TKI treatment. TKI treatment duration pre-stop was longer and proportion treated with second-generation TKI slightly higher outside studies, conceivably affecting the clinical outcome. In summary we show that TKI discontinuation in CML in clinical practice is common and feasible and may be just as successful as when performed within a clinical trial.

Published
2021

5. Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Author

Flygt, Hjalmar, Sandin, Fredrik, Dahlén, Torsten, Dremaine, Arta, Lübking, Anna, Markevärn, Berit, Myhr-Eriksson, Kristina, Olsson, Karin, Olsson-Strömberg, Ulla, Själander, Anders, Söderlund, Stina, Wennström, Lovisa, Wadenvik, Hans, Stenke, Leif, Höglund, Martin, Richter, Johan, Flygt, Hjalmar, Sandin, Fredrik, Dahlén, Torsten, Dremaine, Arta, Lübking, Anna, Markevärn, Berit, Myhr-Eriksson, Kristina, Olsson, Karin, Olsson-Strömberg, Ulla, Själander, Anders, Söderlund, Stina, Wennström, Lovisa, Wadenvik, Hans, Stenke, Leif, Höglund, Martin, and Richter, Johan

Abstract

Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outside clinical trials are limited. In this retrospective study utilising the Swedish CML registry, we examined TKI discontinuation in a population-based setting. Out of 584 patients diagnosed with chronic-phase CML (CML-CP) in 2007-2012, 548 had evaluable information on TKI discontinuation. With a median follow-up of nine years from diagnosis, 128 (23%) discontinued TKI therapy (>= 1 month) due to achieving a DMR (deep molecular response) and 107 (20%) due to other causes (adverse events, allogeneic stem cell transplant, pregnancy, etc). Among those stopping in DMR, 49% re-initiated TKI treatment (median time to restart 4 center dot 8 months). In all, 38 patients stopped TKI within a clinical study and 90 outside a study. After 24 months 41 center dot 1% of patients discontinuing outside a study had re-initiated TKI treatment. TKI treatment duration pre-stop was longer and proportion treated with second-generation TKI slightly higher outside studies, conceivably affecting the clinical outcome. In summary we show that TKI discontinuation in CML in clinical practice is common and feasible and may be just as successful as when performed within a clinical trial.

Published
2021
Full Text
View/download PDF

6. Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry

Author

Flygt, Hjalmar, primary, Sandin, Fredrik, additional, Dahlén, Torsten, additional, Dremaine, Arta, additional, Lübking, Anna, additional, Markevärn, Berit, additional, Myhr‐Eriksson, Kristina, additional, Olsson, Karin, additional, Olsson‐Strömberg, Ulla, additional, Själander, Anders, additional, Söderlund, Stina, additional, Wennström, Lovisa, additional, Wadenvik, Hans, additional, Stenke, Leif, additional, Höglund, Martin, additional, and Richter, Johan, additional

Published
2021
Full Text
View/download PDF

7. Insulin Sensitivity and Diabetic Kidney Disease in Children and Adolescents With Type 2 Diabetes: An Observational Analysis of Data From the TODAY Clinical Trial

Author

Petter Bjornstad, Edward Nehus, Laure El ghormli, Fida Bacha, Ingrid M. Libman, Siripoom McKay, Steven M. Willi, Lori Laffel, Silva Arslanian, Kristen J. Nadeau, S. McKay, M. Haymond, B. Anderson, C. Bush, S. Gunn, H. Holden, S.M. Jones, G. Jeha, S. McGirk, S. Thamotharan, L. Cuttler, E. Abrams, T. Casey, W. Dahms, C. Ievers-Landis, B. Kaminski, M. Koontz, S. MacLeish, P. McGuigan, S. Narasimhan, M. Geffner, V. Barraza, N. Chang, B. Conrad, D. Dreimane, S. Estrada, L. Fisher, E. Fleury-Milfort, S. Hernandez, B. Hollen, F. Kaufman, E. Law, V. Mansilla, D. Miller, C. Muñoz, R. Ortiz, A. Ward, K. Wexler, Y.K. Xu, P. Yasuda, L. Levitt Katz, R. Berkowitz, S. Boyd, B. Johnson, J. Kaplan, C. Keating, C. Lassiter, T. Lipman, G. McGinley, H. McKnight, B. Schwartzman, S. Willi, S. Arslanian, F. Bacha, S. Foster, B. Galvin, T. Hannon, A. Kriska, I. Libman, M. Marcus, K. Porter, T. Songer, E. Venditti, R. Goland, D. Gallagher, P. Kringas, N. Leibel, D. Ng, M. Ovalles, D. Seidman, L. Laffel, A. Goebel-Fabbri, M. Hall, L. Higgins, J. Keady, M. Malloy, K. Milaszewski, L. Rasbach, D.M. Nathan, A. Angelescu, L. Bissett, C. Ciccarelli, L. Delahanty, V. Goldman, O. Hardy, M. Larkin, L. Levitsky, R. McEachern, D. Norman, D. Nwosu, S. Park-Bennett, D. Richards, N. Sherry, B. Steiner, S. Tollefsen, S. Carnes, D. Dempsher, D. Flomo, T. Whelan, B. Wolff, R. Weinstock, D. Bowerman, S. Bristol, J. Bulger, J. Hartsig, R. Izquierdo, J. Kearns, R. Saletsky, P. Trief, P. Zeitler, N. Abramson, A. Bradhurst, N. Celona-Jacobs, J. Higgins, M. Kelsey, G. Klingensmith, K. Nadeau, T. Witten, K. Copeland, E. Boss, R. Brown, J. Chadwick, L. Chalmers, S. Chernausek, A. Hebensperger, C. Macha, R. Newgent, A. Nordyke, D. Olson, T. Poulsen, L. Pratt, J. Preske, J. Schanuel, S. Sternlof, J. Lynch, N. Amodei, R. Barajas, C. Cody, D. Hale, J. Hernandez, C. Ibarra, E. Morales, S. Rivera, G. Rupert, A. Wauters, N. White, A. Arbeláez, J. Jones, T. Jones, M. Sadler, M. Tanner, A. Timpson, R. Welch, S. Caprio, M. Grey, C. Guandalini, S. Lavietes, P. Rose, A. Syme, W. Tamborlane, K. Hirst, S. Edelstein, P. Feit, N. Grover, C. Long, L. Pyle, B. Linder, S.M. Marcovina, J. Harting, J. Shepherd, B. Fan, L. Marquez, M. Sherman, J. Wang, M. Nichols, E. Mayer-Davis, Y. Liu, J. Lima, S. Gidding, J. Puccella, E. Ricketts, R. Danis, A. Domalpally, A. Goulding, S. Neill, P. Vargo, D. Wilfley, D. Aldrich-Rasche, K. Franklin, C. Massmann, D. O’Brien, J. Patterson, T. Tibbs, D. Van Buren, M. Palmert, R. Ratner, D. Dremaine, and J. Silverstein

Subjects
medicine.medical_specialty, business.industry, Renal function, Type 2 Diabetes Mellitus, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, medicine.disease, Article, Metformin, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Nephrology, Internal medicine, medicine, Cumulative incidence, business, Rosiglitazone, Body mass index, Glycemic, medicine.drug
Abstract

Background Diabetic kidney disease is a major cause of premature mortality in type 2 diabetes mellitus (T2DM). Worsening insulin sensitivity independent of glycemic control may contribute to the development of diabetic kidney disease. We investigated the longitudinal association of insulin sensitivity with hyperfiltration and increased albumin excretion in adolescents with T2DM. Study Design Observational prospective cohort study. Setting & Participants 532 TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) participants aged 12 to 17 years with T2DM duration less than 2 years at baseline. The TODAY Study was a multicenter randomized clinical trial that examined the efficacy of 3 treatment regimens (metformin monotherapy, metformin plus rosiglitazone, or metformin plus an intensive lifestyle intervention program) to achieve durable glycemic control. Predictors Natural log–transformed estimated insulin sensitivity (reciprocal of fasting insulin), hemoglobin A1c concentration, age, race-ethnicity, treatment group, body mass index, loss of glycemic control, and hypertension. Outcomes Hyperfiltration was defined as 99th percentile or higher of estimated glomerular filtration rate (≥140mL/min/1.73m2) when referenced to healthy adolescents (NHANES 1999-2002) and albumin-creatinine ratio ≥ 30μg/mg at 3 consecutive annual visits. Results Hyperfiltration was observed in 7.0% of participants at baseline and in 13.3% by 5 years, with a cumulative incidence of 5.0% over 5 years. The prevalence of increased albumin excretion was 6% at baseline and 18% by 5 years, with a cumulative incidence of 13.4%. There was an 8% increase in risk for hyperfiltration per 10% lower estimated insulin sensitivity in unadjusted and adjusted models (P=0.01). Increased albumin excretion was associated with hemoglobin A1c concentration, but not estimated insulin sensitivity. Limitations Longer follow-up is needed to capture the transition from hyperfiltration to rapid glomerular filtration rate decline in youth-onset T2DM. Conclusions Lower estimated insulin sensitivity was associated with risk for hyperfiltration over time, whereas increased albumin excretion was associated with hyperglycemia in youth-onset T2DM.

Published
2017

8. Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study

Author

Samuel S. Gidding, Fida Bacha, Petter Bjornstad, Lorraine E. Levitt Katz, Lynne L. Levitsky, Jane Lynch, Jeanie B. Tryggestad, Ruth S. Weinstock, Laure El ghormli, Joao A.C. Lima, S. McKay, M. Haymond, B. Anderson, C. Bush, S. Gunn, H. Holden, S.M. Jones, G. Jeha, S. McGirk, S. Thamotharan, L. Cuttler, E. Abrams, T. Casey, W. Dahms, C. Ievers-Landis, B. Kaminski, M. Koontz, S. MacLeish, P. McGuigan, S. Narasimhan, M. Geffner, V. Barraza, N. Chang, B. Conrad, D. Dreimane, S. Estrada, L. Fisher, E. Fleury-Milfort, S. Hernandez, B. Hollen, F. Kaufman, E. Law, V. Mansilla, D. Miller, C. Muñoz, R. Ortiz, A. Ward, K. Wexler, Y.K. Xu, P. Yasuda, L. Levitt Katz, R. Berkowitz, S. Boyd, B. Johnson, J. Kaplan, C. Keating, C. Lassiter, T. Lipman, G. McGinley, H. McKnight, B. Schwartzman, S. Willi, S. Arslanian, F. Bacha, S. Foster, B. Galvin, T. Hannon, A. Kriska, I. Libman, M. Marcus, K. Porter, T. Songer, E. Venditti, R. Goland, D. Gallagher, P. Kringas, N. Leibel, D. Ng, M. Ovalles, D. Seidman, L. Laffel, A. Goebel-Fabbri, M. Hall, L. Higgins, J. Keady, M. Malloy, K. Milaszewski, L. Rasbach, D.M. Nathan, A. Angelescu, L. Bissett, C. Ciccarelli, L. Delahanty, V. Goldman, O. Hardy, M. Larkin, L. Levitsky, R. McEachern, D. Norman, D. Nwosu, S. Park-Bennett, D. Richards, N. Sherry, B. Steiner, S. Tollefsen, S. Carnes, D. Dempsher, D. Flomo, T. Whelan, B. Wolff, R. Weinstock, D. Bowerman, S. Bristol, J. Bulger, J. Hartsig, R. Izquierdo, J. Kearns, R. Saletsky, P. Trief, P. Zeitler, N. Abramson, A. Bradhurst, N. Celona-Jacobs, J. Higgins, M. Kelsey, G. Klingensmith, K. Nadeau, T. Witten, K. Copeland, E. Boss, R. Brown, J. Chadwick, L. Chalmers, S. Chernausek, A. Hebensperger, C. Macha, R. Newgent, A. Nordyke, D. Olson, T. Poulsen, L. Pratt, J. Preske, J. Schanuel, S. Sternlof, J. Lynch, N. Amodei, R. Barajas, C. Cody, D. Hale, J. Hernandez, C. Ibarra, E. Morales, S. Rivera, G. Rupert, A. Wauters, N. White, A. Arbeláez, J. Jones, T. Jones, M. Sadler, M. Tanner, A. Timpson, R. Welch, S. Caprio, M. Grey, C. Guandalini, S. Lavietes, P. Rose, A. Syme, W. Tamborlane, K. Hirst, S. Edelstein, P. Feit, N. Grover, C. Long, L. Pyle, B. Linder, S.M. Marcovina, J. Harting, J. Shepherd, B. Fan, L. Marquez, M. Sherman, J. Wang, M. Nichols, E. Mayer-Davis, Y. Liu, J. Lima, S. Gidding, J. Puccella, E. Ricketts, R. Danis, A. Domalpally, A. Goulding, S. Neill, P. Vargo, D. Wilfley, D. Aldrich-Rasche, K. Franklin, C. Massmann, D. O'Brien, J. Patterson, T. Tibbs, D. Van Buren, M. Palmert, R. Ratner, D. Dremaine, and J. Silverstein

Subjects
Male, medicine.medical_specialty, Adolescent, Diet therapy, Heart Ventricles, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Article, Ventricular Function, Left, Rosiglitazone, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, Hypoglycemic Agents, Child, Ejection fraction, biology, business.industry, Type 2 Diabetes Mellitus, Brain natriuretic peptide, medicine.disease, Troponin, Combined Modality Therapy, Metformin, Exercise Therapy, Diabetes Mellitus, Type 1, Blood pressure, Treatment Outcome, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Echocardiography, Pediatrics, Perinatology and Child Health, biology.protein, Cardiology, Drug Therapy, Combination, Female, Thiazolidinediones, business, Body mass index, Biomarkers, Diet Therapy, Follow-Up Studies
Abstract

Objectives To examine cardiac biomarkers over time in youth-onset type 2 diabetes, and relate serum concentrations to cardiovascular disease risk factors, and left ventricular structure and function. Study design TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) was a multicenter randomized trial of 3 treatments including 521 participants with type 2 diabetes, aged 10-17 years, and with 2-6 years of follow-up. Participants were 36% male, obese, and ethnically diverse. Annual serum concentrations of brain natriuretic peptide, troponin, tumor necrosis factor (TNF)-α, receptors 1 and 2 were related to blood pressure, body mass index, hemoglobin A1c, and left ventricular ejection fraction, diastolic function, relative wall thickness, and mass. Results Elevated concentrations of brain natriuretic peptide (≥100 pg/mL), TNF-α (≥5.6 pg/mL) and troponin (≥0.01 ng/mL), were present in 17.8%, 18.3%, and 34.2% of the cohort, respectively, at baseline, and in 15.4%, 17.1%, and 31.1% at the end of the study, with wide variability over time, without persistence in individuals or clear relationship to glycemia or cardiovascular structure/function. TNF receptors concentrations were increased at baseline and not significantly different from end-of-study concentrations. Adverse echocardiographic measures were more likely in the highest TNF receptor tertile (all P Conclusions Elevated serum concentrations of cardiac biomarkers were common in youth with type 2 diabetes, but their clinical significance is unclear and will require further long-term study. Trial registration ClinicalTrials.gov NCT00081328 .

Published
2017

9. Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes

Author

Levitt Katz, Lorraine E., primary, Bacha, Fida, additional, Gidding, Samuel S., additional, Weinstock, Ruth S., additional, El ghormli, Laure, additional, Libman, Ingrid, additional, Nadeau, Kristen J., additional, Porter, Kristin, additional, Marcovina, Santica, additional, McKay, S., additional, Haymond, M., additional, Anderson, B., additional, Bush, C., additional, Gunn, S., additional, Holden, H., additional, Jones, S.M., additional, Jeha, G., additional, McGirk, S., additional, Thamotharan, S., additional, Cuttler, L., additional, Abrams, E., additional, Casey, T., additional, Dahms, W., additional, Ievers-Landis, C., additional, Kaminski, B., additional, Koontz, M., additional, MacLeish, S., additional, McGuigan, P., additional, Narasimhan, S., additional, Geffner, M., additional, Barraza, V., additional, Chang, N., additional, Conrad, B., additional, Dreimane, D., additional, Estrada, S., additional, Fisher, L., additional, Fleury-Milfort, E., additional, Hernandez, S., additional, Hollen, B., additional, Kaufman, F., additional, Law, E., additional, Mansilla, V., additional, Miller, D., additional, Muñoz, C., additional, Ortiz, R., additional, Ward, A., additional, Wexler, K., additional, Xu, Y.K., additional, Yasuda, P., additional, Berkowitz, R., additional, Boyd, S., additional, Johnson, B., additional, Kaplan, J., additional, Keating, C., additional, Lassiter, C., additional, Lipman, T., additional, McGinley, G., additional, McKnight, H., additional, Schwartzman, B., additional, Willi, S., additional, Arslanian, S., additional, Foster, S., additional, Galvin, B., additional, Hannon, T., additional, Kriska, A., additional, Marcus, M., additional, Songer, T., additional, Venditti, E., additional, Goland, R., additional, Gallagher, D., additional, Kringas, P., additional, Leibel, N., additional, Ng, D., additional, Ovalles, M., additional, Seidman, D., additional, Laffel, L., additional, Goebel-Fabbri, A., additional, Hall, M., additional, Higgins, L., additional, Keady, J., additional, Malloy, M., additional, Milaszewski, K., additional, Rasbach, L., additional, Nathan, D.M., additional, Angelescu, A., additional, Bissett, L., additional, Ciccarelli, C., additional, Delahanty, L., additional, Goldman, V., additional, Hardy, O., additional, Larkin, M., additional, Levitsky, L., additional, McEachern, R., additional, Norman, D., additional, Nwosu, D., additional, Park-Bennett, S., additional, Richards, D., additional, Sherry, N., additional, Steiner, B., additional, Tollefsen, S., additional, Carnes, S., additional, Dempsher, D., additional, Flomo, D., additional, Whelan, T., additional, Wolff, B., additional, Bowerman, D., additional, Bristol, S., additional, Bulger, J., additional, Hartsig, J., additional, Izquierdo, R., additional, Kearns, J., additional, Saletsky, R., additional, Trief, P., additional, Zeitler, P., additional, Abramson, N., additional, Bradhurst, A., additional, Celona-Jacobs, N., additional, Higgins, J., additional, Kelsey, M., additional, Klingensmith, G., additional, Witten, T., additional, Copeland, K., additional, Boss, E., additional, Brown, R., additional, Chadwick, J., additional, Chalmers, L., additional, Chernausek, S., additional, Hebensperger, A., additional, Macha, C., additional, Newgent, R., additional, Nordyke, A., additional, Olson, D., additional, Poulsen, T., additional, Pratt, L., additional, Preske, J., additional, Schanuel, J., additional, Sternlof, S., additional, Lynch, J., additional, Amodei, N., additional, Barajas, R., additional, Cody, C., additional, Hale, D., additional, Hernandez, J., additional, Ibarra, C., additional, Morales, E., additional, Rivera, S., additional, Rupert, G., additional, Wauters, A., additional, White, N., additional, Arbeláez, A., additional, Jones, J., additional, Jones, T., additional, Sadler, M., additional, Tanner, M., additional, Timpson, A., additional, Welch, R., additional, Caprio, S., additional, Grey, M., additional, Guandalini, C., additional, Lavietes, S., additional, Rose, P., additional, Syme, A., additional, Tamborlane, W., additional, Hirst, K., additional, Edelstein, S., additional, Feit, P., additional, Grover, N., additional, Long, C., additional, Pyle, L., additional, Linder, B., additional, Harting, J., additional, Shepherd, J., additional, Fan, B., additional, Marquez, L., additional, Sherman, M., additional, Wang, J., additional, Nichols, M., additional, Mayer-Davis, E., additional, Liu, Y., additional, Lima, J., additional, Puccella, J., additional, Ricketts, E., additional, Danis, R., additional, Domalpally, A., additional, Goulding, A., additional, Neill, S., additional, Vargo, P., additional, Wilfley, D., additional, Aldrich-Rasche, D., additional, Franklin, K., additional, Massmann, C., additional, O'Brien, D., additional, Patterson, J., additional, Tibbs, T., additional, Van Buren, D., additional, Palmert, M., additional, Ratner, R., additional, Dremaine, D., additional, and Silverstein, J., additional

Published
2018
Full Text
View/download PDF

10. Insulin Sensitivity and Diabetic Kidney Disease in Children and Adolescents With Type 2 Diabetes: An Observational Analysis of Data From the TODAY Clinical Trial

Author

Bjornstad, Petter, primary, Nehus, Edward, additional, El ghormli, Laure, additional, Bacha, Fida, additional, Libman, Ingrid M., additional, McKay, Siripoom, additional, Willi, Steven M., additional, Laffel, Lori, additional, Arslanian, Silva, additional, Nadeau, Kristen J., additional, McKay, S., additional, Haymond, M., additional, Anderson, B., additional, Bush, C., additional, Gunn, S., additional, Holden, H., additional, Jones, S.M., additional, Jeha, G., additional, McGirk, S., additional, Thamotharan, S., additional, Cuttler, L., additional, Abrams, E., additional, Casey, T., additional, Dahms, W., additional, Ievers-Landis, C., additional, Kaminski, B., additional, Koontz, M., additional, MacLeish, S., additional, McGuigan, P., additional, Narasimhan, S., additional, Geffner, M., additional, Barraza, V., additional, Chang, N., additional, Conrad, B., additional, Dreimane, D., additional, Estrada, S., additional, Fisher, L., additional, Fleury-Milfort, E., additional, Hernandez, S., additional, Hollen, B., additional, Kaufman, F., additional, Law, E., additional, Mansilla, V., additional, Miller, D., additional, Muñoz, C., additional, Ortiz, R., additional, Ward, A., additional, Wexler, K., additional, Xu, Y.K., additional, Yasuda, P., additional, Levitt Katz, L., additional, Berkowitz, R., additional, Boyd, S., additional, Johnson, B., additional, Kaplan, J., additional, Keating, C., additional, Lassiter, C., additional, Lipman, T., additional, McGinley, G., additional, McKnight, H., additional, Schwartzman, B., additional, Willi, S., additional, Arslanian, S., additional, Bacha, F., additional, Foster, S., additional, Galvin, B., additional, Hannon, T., additional, Kriska, A., additional, Libman, I., additional, Marcus, M., additional, Porter, K., additional, Songer, T., additional, Venditti, E., additional, Goland, R., additional, Gallagher, D., additional, Kringas, P., additional, Leibel, N., additional, Ng, D., additional, Ovalles, M., additional, Seidman, D., additional, Laffel, L., additional, Goebel-Fabbri, A., additional, Hall, M., additional, Higgins, L., additional, Keady, J., additional, Malloy, M., additional, Milaszewski, K., additional, Rasbach, L., additional, Nathan, D.M., additional, Angelescu, A., additional, Bissett, L., additional, Ciccarelli, C., additional, Delahanty, L., additional, Goldman, V., additional, Hardy, O., additional, Larkin, M., additional, Levitsky, L., additional, McEachern, R., additional, Norman, D., additional, Nwosu, D., additional, Park-Bennett, S., additional, Richards, D., additional, Sherry, N., additional, Steiner, B., additional, Tollefsen, S., additional, Carnes, S., additional, Dempsher, D., additional, Flomo, D., additional, Whelan, T., additional, Wolff, B., additional, Weinstock, R., additional, Bowerman, D., additional, Bristol, S., additional, Bulger, J., additional, Hartsig, J., additional, Izquierdo, R., additional, Kearns, J., additional, Saletsky, R., additional, Trief, P., additional, Zeitler, P., additional, Abramson, N., additional, Bradhurst, A., additional, Celona-Jacobs, N., additional, Higgins, J., additional, Kelsey, M., additional, Klingensmith, G., additional, Nadeau, K., additional, Witten, T., additional, Copeland, K., additional, Boss, E., additional, Brown, R., additional, Chadwick, J., additional, Chalmers, L., additional, Chernausek, S., additional, Hebensperger, A., additional, Macha, C., additional, Newgent, R., additional, Nordyke, A., additional, Olson, D., additional, Poulsen, T., additional, Pratt, L., additional, Preske, J., additional, Schanuel, J., additional, Sternlof, S., additional, Lynch, J., additional, Amodei, N., additional, Barajas, R., additional, Cody, C., additional, Hale, D., additional, Hernandez, J., additional, Ibarra, C., additional, Morales, E., additional, Rivera, S., additional, Rupert, G., additional, Wauters, A., additional, White, N., additional, Arbeláez, A., additional, Jones, J., additional, Jones, T., additional, Sadler, M., additional, Tanner, M., additional, Timpson, A., additional, Welch, R., additional, Caprio, S., additional, Grey, M., additional, Guandalini, C., additional, Lavietes, S., additional, Rose, P., additional, Syme, A., additional, Tamborlane, W., additional, Hirst, K., additional, Edelstein, S., additional, Feit, P., additional, Grover, N., additional, Long, C., additional, Pyle, L., additional, Linder, B., additional, Marcovina, S.M., additional, Harting, J., additional, Shepherd, J., additional, Fan, B., additional, Marquez, L., additional, Sherman, M., additional, Wang, J., additional, Nichols, M., additional, Mayer-Davis, E., additional, Liu, Y., additional, Lima, J., additional, Gidding, S., additional, Puccella, J., additional, Ricketts, E., additional, Danis, R., additional, Domalpally, A., additional, Goulding, A., additional, Neill, S., additional, Vargo, P., additional, Wilfley, D., additional, Aldrich-Rasche, D., additional, Franklin, K., additional, Massmann, C., additional, O’Brien, D., additional, Patterson, J., additional, Tibbs, T., additional, Van Buren, D., additional, Palmert, M., additional, Ratner, R., additional, Dremaine, D., additional, and Silverstein, J., additional

Published
2018
Full Text
View/download PDF

11. Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes

Author

Lorraine E. Levitt Katz, Fida Bacha, Samuel S. Gidding, Ruth S. Weinstock, Laure El ghormli, Ingrid Libman, Kristen J. Nadeau, Kristin Porter, Santica Marcovina, S. McKay, M. Haymond, B. Anderson, C. Bush, S. Gunn, H. Holden, S.M. Jones, G. Jeha, S. McGirk, S. Thamotharan, L. Cuttler, E. Abrams, T. Casey, W. Dahms, C. Ievers-Landis, B. Kaminski, M. Koontz, S. MacLeish, P. McGuigan, S. Narasimhan, M. Geffner, V. Barraza, N. Chang, B. Conrad, D. Dreimane, S. Estrada, L. Fisher, E. Fleury-Milfort, S. Hernandez, B. Hollen, F. Kaufman, E. Law, V. Mansilla, D. Miller, C. Muñoz, R. Ortiz, A. Ward, K. Wexler, Y.K. Xu, P. Yasuda, R. Berkowitz, S. Boyd, B. Johnson, J. Kaplan, C. Keating, C. Lassiter, T. Lipman, G. McGinley, H. McKnight, B. Schwartzman, S. Willi, S. Arslanian, S. Foster, B. Galvin, T. Hannon, A. Kriska, M. Marcus, T. Songer, E. Venditti, R. Goland, D. Gallagher, P. Kringas, N. Leibel, D. Ng, M. Ovalles, D. Seidman, L. Laffel, A. Goebel-Fabbri, M. Hall, L. Higgins, J. Keady, M. Malloy, K. Milaszewski, L. Rasbach, D.M. Nathan, A. Angelescu, L. Bissett, C. Ciccarelli, L. Delahanty, V. Goldman, O. Hardy, M. Larkin, L. Levitsky, R. McEachern, D. Norman, D. Nwosu, S. Park-Bennett, D. Richards, N. Sherry, B. Steiner, S. Tollefsen, S. Carnes, D. Dempsher, D. Flomo, T. Whelan, B. Wolff, D. Bowerman, S. Bristol, J. Bulger, J. Hartsig, R. Izquierdo, J. Kearns, R. Saletsky, P. Trief, P. Zeitler, N. Abramson, A. Bradhurst, N. Celona-Jacobs, J. Higgins, M. Kelsey, G. Klingensmith, T. Witten, K. Copeland, E. Boss, R. Brown, J. Chadwick, L. Chalmers, S. Chernausek, A. Hebensperger, C. Macha, R. Newgent, A. Nordyke, D. Olson, T. Poulsen, L. Pratt, J. Preske, J. Schanuel, S. Sternlof, J. Lynch, N. Amodei, R. Barajas, C. Cody, D. Hale, J. Hernandez, C. Ibarra, E. Morales, S. Rivera, G. Rupert, A. Wauters, N. White, A. Arbeláez, J. Jones, T. Jones, M. Sadler, M. Tanner, A. Timpson, R. Welch, S. Caprio, M. Grey, C. Guandalini, S. Lavietes, P. Rose, A. Syme, W. Tamborlane, K. Hirst, S. Edelstein, P. Feit, N. Grover, C. Long, L. Pyle, B. Linder, J. Harting, J. Shepherd, B. Fan, L. Marquez, M. Sherman, J. Wang, M. Nichols, E. Mayer-Davis, Y. Liu, J. Lima, J. Puccella, E. Ricketts, R. Danis, A. Domalpally, A. Goulding, S. Neill, P. Vargo, D. Wilfley, D. Aldrich-Rasche, K. Franklin, C. Massmann, D. O'Brien, J. Patterson, T. Tibbs, D. Van Buren, M. Palmert, R. Ratner, D. Dremaine, and J. Silverstein

Subjects
Blood Glucose, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Overweight, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Diabetes mellitus, medicine, Humans, Insulin, Child, Dyslipidemias, Glycemic, Glycated Hemoglobin, Inflammation, business.industry, Cholesterol, Type 2 Diabetes Mellitus, Cholesterol, LDL, medicine.disease, Lipids, Diabetes Mellitus, Type 2, chemistry, Pediatrics, Perinatology and Child Health, Disease Progression, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitors, medicine.symptom, business, Dyslipidemia
Abstract

Objectives Data regarding atherogenic dyslipidemia and the inflammation profile in youth with type 2 diabetes is limited and the effect of insulin therapy on these variables has not previously been studied in youth. We determined the impact of insulin therapy on lipid and inflammatory markers in youth with poorly controlled type 2 diabetes. Study design In the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) multicenter trial, 285 participants failed to sustain glycemic control on randomized treatment (primary outcome, glycated hemoglobin A1c [HbA1c] at ≥8% for 6 months); 363 maintained glycemic control (never reached primary outcome). Statins were used for a low-density lipoprotein cholesterol of ≥130 mg/dL. Upon reaching the primary outcome, insulin was started. Changes in lipids and inflammatory markers (slopes over time) were examined. Results Progression of dyslipidemia was related to glycemic control. In those with the primary outcome, insulin therapy impacted HbA1c modestly, and dampened the increase in total cholesterol, low-density lipoprotein cholesterol, and total apolipoprotein B, although statin use increased from 8.6% to 22% year after the primary outcome. The increase in triglycerides and plasma nonesterified fatty acids stabilized after insulin was started, independent of HbA1c. There was an increase in high-sensitivity C-reactive protein that continued after insulin initiation, related to HbA1c and percent overweight. Conclusions Worsening dyslipidemia and inflammation over time raise concern regarding premature development of atherosclerosis in youth with type 2 diabetes. Insulin therapy has a limited benefit in the absence of glycemic control. Strategies to achieve better glycemic control are needed. Trial registration ClinicalTrials.gov : NCT00081328 .

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results